Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Equity (2017 - 2025)

Aclaris Therapeutics has reported Return on Equity over the past 9 years, most recently at 0.62% for Q4 2025.

  • Quarterly results put Return on Equity at 0.62% for Q4 2025, up 32.0% from a year ago — trailing twelve months through Dec 2025 was 0.62% (up 32.0% YoY), and the annual figure for FY2025 was 0.53%, up 31.0%.
  • Return on Equity for Q4 2025 was 0.62% at Aclaris Therapeutics, up from 1.15% in the prior quarter.
  • Over the last five years, Return on Equity for ACRS hit a ceiling of 0.27% in Q2 2021 and a floor of 1.15% in Q3 2025.
  • Median Return on Equity over the past 5 years was 0.48% (2021), compared with a mean of 0.57%.
  • Biggest five-year swings in Return on Equity: skyrocketed 42bps in 2024 and later crashed -86bps in 2025.
  • Aclaris Therapeutics' Return on Equity stood at 0.43% in 2021, then increased by 1bps to 0.43% in 2022, then plummeted by -38bps to 0.59% in 2023, then tumbled by -58bps to 0.94% in 2024, then soared by 34bps to 0.62% in 2025.
  • The last three reported values for Return on Equity were 0.62% (Q4 2025), 1.15% (Q3 2025), and 1.0% (Q2 2025) per Business Quant data.